A study to measure the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
Official registry: https://clinicaltrials.gov/study/NCT07116967 · Bristol-Myers Squibb · enrollment listed as 3,040
Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Deucravacitinib, or Ustekinumab. The registry lists allocation as randomized. A study to measure the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
They plan to enroll about 3,040 people at 411 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis
Interventions: Deucravacitinib, Ustekinumab
Primary outcome (registry wording): Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
+ 289 sites outside the US on the same record
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
NCT01848028 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.
NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit
The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.
NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary